Stock 300142 WALVAX BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Walvax Biotechnology Co., Ltd.

Equities

300142

CNE100000WN2

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
14.14 CNY -0.77% Intraday chart for Walvax Biotechnology Co., Ltd. -0.49% -39.86%
06:35am Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial MT
Apr. 24 Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial
MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
China's drugmakers can't sell mRNA shots but haven't quit yet
RE
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.
CI
Walvax Biotechnology Co., Ltd.'s Equity Buyback announced on April 5, 2023, has expired with 2,000,000 shares, representing 0.12% for CNY 72.2 million.
CI
Walvax Biotechnology's 2023 Profit Falls 42%
MT
Walvax Biotechnology Co., Ltd. Proposes Cash Profit Distribution for 2023
CI
Walvax Biotechnology Scraps Plan to Issue Convertible Bonds
MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Walvax Biotechnology Sees Up to 45% Drop in 2023 Profit
MT
Chinese Shares End Mixed as Stimulus Hopes Fade; Walvax Falls 6% on Downbeat Profit Outlook
MT
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China
MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.
CI
Lanvin Group Chief Executive Joann Cheng Steps Down
MT
Walvax Biotechnology Registers Pneumonia Vaccines in Philippines
MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Walvax Biotechnology's Unit Gets License to Market Pneumonia Vaccine in Indonesia; Shares Up 3%
MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.
CI
Walvax Biotechnology Unit Gets Nod to Carry Out Vaccine's Phase III Trial in Indonesia
MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300142 Stock
  4. News Walvax Biotechnology Co., Ltd.